Model Comparison
Model Editorial Structural Class Conf SETL Theme
@cf/meta/llama-4-scout-17b-16e-instruct lite ND ND 0.80
@cf/meta/llama-4-scout-17b-16e-instruct lite 0.00 -0.24 Neutral 0.80 0.24 Healthcare Access
Section @cf/meta/llama-4-scout-17b-16e-instruct lite @cf/meta/llama-4-scout-17b-16e-instruct lite Delta
Preamble ND ND
Article 1 ND ND
Article 2 ND ND
Article 3 ND ND
Article 4 ND ND
Article 5 ND ND
Article 6 ND ND
Article 7 ND ND
Article 8 ND ND
Article 9 ND ND
Article 10 ND ND
Article 11 ND ND
Article 12 ND ND
Article 13 ND ND
Article 14 ND ND
Article 15 ND ND
Article 16 ND ND
Article 17 ND ND
Article 18 ND ND
Article 19 ND ND
Article 20 ND ND
Article 21 ND ND
Article 22 ND ND
Article 23 ND ND
Article 24 ND ND
Article 25 ND ND
Article 26 ND ND
Article 27 ND ND
Article 28 ND ND
Article 29 ND ND
Article 30 ND ND
ND How long til we're all on Ozempic? (asteriskmag.com)
461 points by thehoff 520 days ago | 1584 comments on HN ~lite vlite-2.0
Summary ~lite
The article discusses the potential growth and benefits of GLP-1 medications like Ozempic in the US market.
Lite evaluation by llama-4-scout-wai-psq · editorial channel only · no per-section breakdown available
Longitudinal · 2 evals
+1 0 −1 HN
Audit Trail 5 entries
2026-03-14 00:56 eval_success PSQ evaluated: g-PSQ=0.440 (3 dims) - -
2026-03-14 00:56 eval Evaluated by llama-4-scout-wai-psq: +0.44 (Moderate positive)
2026-03-14 00:52 eval_success Lite evaluated: Neutral (-0.10) - -
2026-03-14 00:52 eval Evaluated by llama-4-scout-wai: -0.10 (Neutral)
reasoning
The article discusses the potential benefits and usage of GLP-1 drugs like Ozempic, with no explicit human rights discus
2026-03-14 00:52 rater_validation_warn Lite validation warnings for model llama-4-scout-wai: 1W 1R - -